Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease
Science Translational Medicine · 14.10.2026 · 18 (871)
DOI: 10.1126/scitranslmed.aec5740 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Science Translational Medicine, erschienen am 14.10.2026. Verfasst von Borislav Dejanovic und 21 weiteren Autor:innen. Beteiligte Einrichtung: Vigil Neuroscience, a Sanofi company, Watertown, MA 02472, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Membrane Glycoproteins, Receptors, Immunologic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Microglial dysfunction is increasingly implicated in Alzheimer’s disease (AD) pathogenesis, with loss-of-function variants in the microglial receptor TREM2 as major risk factors for late-onset AD. We report VG-3927, an oral, CNS-penetrant small-molecule TREM2 agonist that engages the transmembrane domains of TREM2 and its adaptor DAP12 to promote higher-order receptor complex formation and downstream signaling. VG-3927 and tool compound VG-3909 exhibited (sub)nanomolar potency, cooperated with endogenous ligands including amyloid-β (Aβ), and restored signaling in disease-associated TREM2 variants. In human iPSC-derived neuron-microglia-astrocyte cultures, VG-3927 reduced inflammatory cytokines and markers of neuronal damage. In 5xFAD amyloidosis mice expressing the common variant of hTREM2 (5xFAD;hTREM2 CV ), VG-3909 induced neuroprotective transcriptional reprogramming of microglia, particularly in the plaque niche; enhanced Aβ phagocytosis; and boosted brain glucose metabolism. By contrast, a TREM2 agonist antibody, which may be sequestered by soluble TREM2 (sTREM2), failed to engage plaque microglia. In a first-in-human, randomized, double-blind, placebo-controlled phase 1 trial (NCT06343636, n = 115), VG-3927 was well tolerated across single and multiple ascending doses of up to 140 milligrams. Pharmacokinetics supported once-daily dosing with high CNS penetration (CSF-to-unbound plasma ratio of 0.91). VG-3927 induced dose-dependent reductions in CSF sTREM2, a biomarker of target engagement, consistent across healthy and elderly participants and participants with AD, supporting further clinical development in AD under the new designation SAR448851.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vigil Neuroscience, a Sanofi company, Watertown, MA 02472, USA.
- Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO 63110, USA.
ORCID-Profile: Borislav Dejanovic, Matthew D Figley, Elizabeth Weisman, Frederick W Gergits, Kelley Larson, Abigail Renoux, Ryan O'Mara, Jade H Clarkson, Marion T Turnbull, Andreas Meier, Marco Colonna, Jessica Stromme, David Gray, Evan A Thackaberry, Christian Mirescu
Zitieren
APA
Dejanovic, B., Figley, M. D., Weisman, E., Kiragasi, B., Gergits, F. W., Larson, K., Renoux, A., Rajagovindan, R., Pandya, B., Houze, J., Huang, L., Gaudreault, F., O'Mara, R., Clarkson, J. H., Turnbull, M. T., Meier, A., Colonna, M., Stromme, J., Gray, D., …, & Mirescu, C. (2026). Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease. Science Translational Medicine, 18(871). https://doi.org/10.1126/scitranslmed.aec5740
Vancouver
Dejanovic B, Figley MD, Weisman E, Kiragasi B, Gergits FW, Larson K, et al. Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease. Science Translational Medicine. 2026;18(871). doi:10.1126/scitranslmed.aec5740
BibTeX
@article{Dejanovic2026,
author = {Dejanovic, Borislav and Figley, Matthew D and Weisman, Elizabeth and Kiragasi, Beril and Gergits, Frederick W and Larson, Kelley and Renoux, Abigail and Rajagovindan, Raj and Pandya, Bhaumik and Houze, Jonathan and Huang, Liyue and Gaudreault, Francois and O'Mara, Ryan and Clarkson, Jade H and Turnbull, Marion T and Meier, Andreas and Colonna, Marco and Stromme, Jessica and Gray, David and Thackaberry, Evan A and Kaufmann, Petra and Mirescu, Christian},
title = {Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {871},
doi = {10.1126/scitranslmed.aec5740}
}
EUVIMED